The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
Abstract
As many as 45% of patients with major depressive episode also meet DSM-IV criteria for bipolar II (BP II) disorder. Although some clinicians advocate using a mood stabilizer in treating BP II depression, antidepressant monotherapy has been less well studied in this disorder. As part of a prospective, placebo-controlled, relapse-prevention study in 839 patients, the efficacy and safety of short- and long-term fluoxetine treatment in patients with BP II major depression compared with patients with unipolar (UP) major depression was retrospectively examined. Eighty-nine BP II patients (mean age, 41+/-11 years) were compared with 89 age- and gender-matched UP patients and with 661 unmatched UP patients (mean age, 39+/-11 years). All received short-term fluoxetine therapy at 20 mg daily for up to 12 weeks. Complete remission was defined as a final Hamilton Rating Scale for Depression score < or = 7 by week 9 that was then maintained for 3 additional weeks. Remitted patients were then randomly assigned to receive double-blind treatment with one of the following: (1) fluoxetine 20 mg daily for 52 weeks; (2) fluoxetine for 38 weeks, then placebo for 14 weeks; (3) fluoxetine for 14 weeks, then placebo for 38 weeks; or (4) placebo for 52 weeks. Antidepressant efficacy was similar in BP and UP patients during short-term therapy. Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients. During long-term relapse-prevention therapy, relapse rates were similar in BP II and UP patients (p = NS). During short-term fluoxetine therapy, three BP II (3.8%) versus no matched UP (p = NS) and 0.3% unmatched UP (p = 0.01) patients had a "manic switch." During long-term fluoxetine therapy, one (2%) BP II and three (1%) unmatched UP patients (one taking placebo) had a manic switch (p = NS). In conclusion, fluoxetine may be a safe and effective antidepressant monotherapy for the short-term treatment of BP II depression with a relatively low manic switch rate. Fluoxetine may also be effective in relapse-prevention therapy in patients with BP II disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it did not report whether fluoxetine was superior to placebo in BDII.”
In the citing paper
“Finally, a post hoc analysis of a large 12‐month placebo‐controlled trial found that response rates to fluoxetine were similar in BDII and MDD.468”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Akiskal, H. S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140032004 · Cited by 679
Weissman, M. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770350030002 · Cited by 644
Antidepressant-induced mania and cycle acceleration: a controversy revisited
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1130 · Cited by 608
Induction of Mania with Selective Serotonin Re-uptake Inhibitors and Tricyclic Antidepressants
Peet, M. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.4.549 · Cited by 474
Can antidepressants cause mania and worsen the course of affective illness?
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.11.1403 · Cited by 398
Long-term stability of polarity distinctions in the affective disorders
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.385 · Cited by 357
Outcome of Bipolar Disorder on Long-Term Treatment with Lithium
O'Connell, R. A., Mayo, J. A., Flatow, L., Cuthbertson, B., & O'Brien, B. E. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.1.123 · Cited by 333
A prospective follow-up of patients with bipolar and primary unipolar affective disorder
Winokur, G. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180059006 · Cited by 249
Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice
Benazzi, F. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)01421-8 · Cited by 229
Research works printed but not linked: 4
- Dunner, 1983, Psychiatr Dev, 1, 75
- Peselow, 1982, Psychiatr Clin (Basel), 15, 124
- Quitkin, 1981, Psychopharmacol Bull, 17, 142
- Kupfer, 1988, Arch Gen Psychiatry, 145, 804
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Self-citationGhaemi, S. N., Ko, J. Y., & Goodwin, F. E. I. K. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700202 · Cited by 456
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
“Amsterdam et al (Amsterdam et al 1998) compared fluoxetine in unipolar depressed with fluoxetine in bipolar II depressed patients in acute and long-term treatment (up to one year).”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“There is some, but less rigorous evidence for antidepressant monotherapy (e.g., fl uoxetine (Amsterdam et al. 1998; Amsterdam and Brunswick 2003), venlafaxine (Amsterdam 1998; Amsterdam and Garcia-Espana 2000) and citalopram (Parker et al. 2006) (all CE1, RG 4).”
Result
Metadata
- Authors
- Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., & Beasley, C.
- Affiliations
- Rush University Medical Center (US)
- ORCID
- Beasley, Charles
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1998-12
- Volume
- 18
- Issue
- 6
- Pages
- 435-440
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2317383367
- Cited by
- 167
- References
- 23
- Citations by year
- 2025: 2 · 2023: 2 · 2021: 1 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 7 · 2012: 3
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- bipolar II disorder, major depressive episode, fluoxetine, antidepressant monotherapy, manic switch, relapse prevention, unipolar major depression, treatment efficacy, drug safety, adverse events, remission, mood stabilizers, long-term maintenance therapy, relapse rate
- MeSH terms
- Adolescent, Adult, Aged, Bipolar Disorder, Child, Double-Blind Method, Female, Fluoxetine, Headache, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Recurrence, Retrospective Studies, Treatment Outcome, Age of Onset, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode. https://app.cochat.ai/papers/10.1097/00004714-199812000-00003
- The paper
- Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., & Beasley, C. (1998). Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199812000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.